Objective: Complex genetic mechanisms are involved in the vulnerability to depressive disorders and cognitive dysfunctions found in depression. This study was performed to explore the effect of the familial risk for depression on electrophysiological correlates of attentional functions as demonstrated by an event-related potential (ERP) go/no-go experiment. Methods: The component P3b as an indicator of target detection processing was investigated in two groups of healthy subjects with or without a family history of depression (n = 14 each). An electrophysiological source localization method (LORETA) was employed to allow a neuro-anatomical interpretation for the ERP data. Results: The group with a familial risk for depression showed a reduced P3b amplitude over left temporal areas in contrast to the control group. This two-dimensional effect was associated with a significantly reduced activation of the left middle temporal gyrus. Conclusions: The P3b amplitude decrement might represent a neurocognitive vulnerability marker for the development of depression.

Keywords:
Depression, Event-related potentials, P3b component, vulnerability marker, Target detection, Source analysis
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.